- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Participating Faculty: Balancing Therapeutic Safety and Efficacy to Improve Clinical and Economic Outcomes in Schizophrenia [CME/CPE]
Faculty
Daniel C. Javitt, MD, PhD
Director
Schizophrenia Research
Nathan Kline Institute
Orangeburg, New York
Professor and Director
Division of Experimental Therapeutics
Columbia University
New York, New York
Junqing Liu, PhD, MSW
Research Scientist
National Committee for Quality Assurance
Washington, District of Columbia
Editorial Support
Mei T. Liu, PharmD, BCPP
Clinical Assistant Professor
Department of Pharmacy Practice and Administration
Ernest Mario School of Pharmacy
Rutgers, the State University of New Jersey
New Brunswick, New Jersey
Psychiatry Clinical Pharmacist
Princeton House Behavioral Health
Princeton, New Jersey
Megan Maroney, PharmD, BCPP
Clinical Assistant Professor
Department of Pharmacy Practice and Administration
Ernest Mario School of Pharmacy
Rutgers, the State University of New Jersey
New Brunswick, New Jersey
Clinical Psychiatric Pharmacist
Monmouth Medical Center
Long Branch, New Jersey
A. Scott Mathis, PharmD
Regional Directory of Pharmacy
Pharmacy Department
Monmouth Medical Center
Long Branch, New Jersey
Faculty Disclosures
Daniel C. Javitt, MD, PhD, has disclosed the following relevant commercial financial relationships or affiliations in the past 12 months:
Grant/research support: Pfizer Inc, Roche
Consultant: Bristol-Myers Squibb, EnVivo, Lilly, Omeros, Otsuka, SK Biopharmaceuticals, Sunovion, Takeda
Stock/shareholder: Glytech
Junqing Liu, PhD, MSW; Mei T. Liu, PharmD, BCPP; Megan Maroney, PharmD, BCPP; and A. Scott Mathis, PharmD, have no relevant financial relationships with commercial interests to disclose.
The American Journal of Managed Care
Publishing staff—Jeff D. Prescott, PharmD, RPh; Ida Delmendo; and Tara Petersen have no relevant financial relationships with commercial interests to disclose.
National Committee for Quality Assurance (NCQA)
Planning staff—Bart Ecker, Jackie Lombos, and Jennifer D’Alessandro have no relevant financial relationships with commercial interests to disclose.
Pharmacy Times Office of Continuing Professional Education
Planning staff—David Heckard; Steve Lin, PharmD, RPh; Donna Fausak; and Nathalie Harden have no relevant financial relationships with commercial interests to disclose.
Off-label Disclosure and Disclaimer
The contents of this CME/CE supplement may include information regarding the use of products that may be inconsistent with or outside the approved labeling for these products in the United States. Physicians and pharmacists should note that the use of these products outside current approved labeling is considered experimental and are advised to consult prescribing information for these products.
For additional information about approved uses, including approved indications, contraindications, and warnings, participants are advised to consult prescribing information for all products discussed. The information provided in this CME/CE activity is for continuing medical and pharmacy education purposes only and is not meant to substitute for the independent medical or pharmacy judgment of a physician or pharmacist relative to diagnostic, treatment, or management options for a specific patient’s medical condition.
The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of The American Journal of Managed Care, Pharmacy Times Office of Continuing Professional Education, and National Committee for Quality Assurance, or any of the companies that provided commercial support for this CME/CE activity.
Signed disclosures are on file at the office of The American Journal of Managed Care, Plainsboro, New Jersey.
Schizophrenia is a complex psychiatric disorder that is linked to substantial clinical and economic burdens. This supplement to The American Journal of Managed Care is designed to provide a detailed clinical understanding of schizophrenia, discuss the far-reaching impact of disease on patient health and quality of life, review the various pharmacologic and nonpharmacologic treatment options, and examine the managed care implications associated with schizophrenia and its management.
